非小细胞肺癌术后评估及中医药治疗研究进展
Research Progress of Non-Small Cell Lung Cancer Postoperative Evaluation and Traditional Chinese Medicine Treatment
DOI: 10.12677/ACM.2019.911203, PDF,    科研立项经费支持
作者: 陆恩昊*, 李和根：上海中医药大学附属龙华医院，上海
关键词: 非小细胞肺癌；术后；中医药；研究进展；NSCLC； Postoperative； TCM； Research Progress
摘要: 癌症是如今世界范围内的一大难题，据2019年统计，肺癌发病率在癌症发病率中均位居第二，死亡率在癌症相关死亡中位居第一，其中非小细胞肺癌占肺癌发病率的绝大多数，早期非小细胞肺癌以手术治疗为主要治疗措施，然而预防术后肿瘤及减轻术后化疗等带来的副反应仍是现今待解决的一大难题。早在19世纪70年代，国医大师刘嘉湘就提出了“扶正抗癌”的治疗思想，大量研究证明中医药治疗在提高肿瘤患者生存率、降低复发转移、改善生存质量、辅助治疗中降低西药毒副反应等方面均有显著疗效，本文将就非小细胞肺癌术后评估及中医药治疗研究进展进行整理总结。
Abstract: Cancer is a worldwide problem nowadays. According to the 2019 statistics, the incidence of lung cancer is the second highest among all cancers, while the mortality rate is the first among cancer-related deaths. Non-small cell lung cancer (NSCLC) accounts for the vast majority of lung cancer incidence whose main treatment is surgical excision. However, it remains a difficult problem to prevent postoperative tumor and reduce the side effects of postoperative chemotherapy. In the 1870s, Liu Jiaxiang, a Chinese medicine master, put forward the idea of “Treating Cancer by Strengthening Vital Qi”. A large number of studies have proved that traditional Chinese medicine therapy has significant effects in improving the survival rate of tumor patients, reducing recurrence and metastasis, improving the quality of life, and reducing toxic and side effects of western medicine in adjuvant therapy. This paper will summarize the research progress of the postoperative evaluation of NSCLC and traditional Chinese medicine (TCM) treatment.
文章引用：陆恩昊, 李和根. 非小细胞肺癌术后评估及中医药治疗研究进展[J]. 临床医学进展, 2019, 9(11): 1315-1322. https://doi.org/10.12677/ACM.2019.911203

参考文献

[1] Siege, R.L., Miller, K.D. and Jemal, A. (2019) Cancer Statistics, 2019. CA: A Cancer Journal for Clinicians, 69, 7-34. [Google Scholar] [CrossRef] [PubMed]
[2] Mathers, C., Parkin, D.M., Pineros, M., Znaor, A., et al. (2019) Estimating the Global Cancer Incidence and Mortality in 2018: GLOBOCAN Sources and Methods. International Journal of Can-cer, 144, 1941-1953. [Google Scholar] [CrossRef] [PubMed]
[3] Edwards, B.K., Brown, M.L., Wingo, P.A., et al. (2005) Annual Report to the Nation on the Status of Cancer. Journal of the National Cancer Institute, 97, 1407-1427. [Google Scholar] [CrossRef] [PubMed]
[4] Atlanta, G.A. (2019) American Cancer Society: Cancer Facts and Figures 2019. American Cancer Society, 15, 321-387. [Google Scholar] [CrossRef] 
[5] Howlader, N., Noone, A.M., Krapcho, M., et al. (2018) SEER Cancer Statistics Review (CSR) 1975-2014. National Cancer Institute, Bethesda, MD.
https://seer.cancer.gov/archive/csr/1975_2014/
[6] He, J. and Chen, W.Q. (2012) Chinese Cancer Registry Annu-al Report 2012. Military Medical Science Press, Beijing, 12.
[7] Herbst, R.S., Morgensztern, D. and Boshoff, C. (2018) The Biology and Management of Non-Small Cell Lung Cancer. Nature, 533, 446-454. [Google Scholar] [CrossRef] [PubMed]
[8] Siegel, R.L., Miller, K.D. and Jemal, A. (2015) Cancer Statistics, 2015. CA: A Cancer Journal for Clinicians, 65, 5-29. [Google Scholar] [CrossRef] [PubMed]
[9] Spira, A. and Ettinger, D.S. (2004) Multidisciplinary Management of Lung Cancer. The New England Journal of Medicine, 350, 379-392. [Google Scholar] [CrossRef] 
[10] Yu James, B., Soulos Pamela, R., Cramer Laura, D., Decker Roy, H., Kim Anthony, W. and Gross Cary, P. (2015) Com-parative Effectiveness of Surgery and Radiosurgery for Stage I Non-Small Cell Lung Cancer. Cancer, 121, 2341-2349. [Google Scholar] [CrossRef] [PubMed]
[11] 连珞宇. 胸腔镜与小切口根治性切除术治疗早期非小细胞肺癌患者的临床效果[J]. 医疗装备, 2019, 32(6): 5-6.
[12] Whitson, B.A., Groth, S.S., Duval, S.J., et al. (2008) Surgery for Ear-ly-Stage Non-Small Cell Lung Cancer: A Systematic Review of the Video-Assisted Thoracoscopic Surgery versus Thoracotomy Approaches to Lobectomy. Annals of Thoracic Surgery, 86, 2008-2018. [Google Scholar] [CrossRef] [PubMed]
[13] 潘峰, 顾爱琴, 王韡旻, 姜丽岩. 免疫治疗药物nivolumab用于非小细胞肺癌治疗的研究进展[J]. 世界临床药物, 2016, 37(10): 717-720.
[14] Fiala, O., Pesek, M., Finek, J., et al. (2016) Prognostic Significance of Serum Tumor Markers in Patients with Advanced-Stage NSCLC Treated with Pemetrexed-Based Chemotherapy. Anticancer Research, 36, 461-466.
[15] Pavicevic, R., Milicic, J., Bubanovic, G., et al. (1998) Serum Tumor Marker CYFRA 21-1 in the Diagnostics of NSCLC Lung Cancer. Collegium Antropologicum, 22, 629-635.
[16] Muley, T., Fetz, T.H., Dienemann, H., et al. (2008) Tumor Volume and Tumor Marker Index Based on CYFRA 21-1 and CEA Are Strong Prognostic Factors in Operated Early Stage NSCLC. Lung Cancer, 60, 408-415. [Google Scholar] [CrossRef] [PubMed]
[17] Ferrigno, D., Buccheri, G. and Giordano, C. (2003) Neu-ron-Specific Enolase Is an Effective Tumour Marker in Non-Small Cell Lung Cancer (NSCLC). Lung Cancer, 41, 311-320. [Google Scholar] [CrossRef] 
[18] Yu, D.F., Du, K.Q., Liu, T.F. and Chen, G. (2013) Prognostic Value of Tumor Markers, NSE, CA125 and SCC, in Operable NSCLC Patients. International Journal of Molecular Sciences, 14, 11145-11156. [Google Scholar] [CrossRef] [PubMed]
[19] 黄汉琮, 陈乾华, 杨晓蕊. CA199、TMPRSS4在早期非小细胞肺癌组织的表达及在肿瘤血管形成中的作用[J]. 中国老年学杂志, 2019, 39(4): 817-818.
[20] Plaks, V., Koopman, C.D. and Werb, Z. (2013) Circulating Tumor Cells. Science, 341, 1186-1188. [Google Scholar] [CrossRef] [PubMed]
[21] Hashimoto, M., Tanaka, F., Yoneda, K., et al. (2018) Positive Corre-lation between Postoperative Tumor Recurrence and Changes in Circulating Tumor Cell Counts in Pulmonary Venous Blood (pvCTC) during Surgical Manipulation in Non-Small Cell Lung Cancer. Journal of Thoracic Disease, 10, 298-306. [Google Scholar] [CrossRef] [PubMed]
[22] 付晓飞, 杨之斌, 殷正丰. 血小板与循环肿瘤细胞[J]. 肿瘤, 2014, 34(3): 286-290.
[23] Heerboth, S., Housman, G., Leary, M., et al. (2015) EMT and Tumor Metastasis. Clinical and Translational Medicine, 4, 6-19. [Google Scholar] [CrossRef] [PubMed]
[24] 林赟, 石毅, 薛洋. 非小细胞肺癌患者进行手术前后其循环肿瘤细胞测量值的变化与其肿瘤复发转移的相关性[J]. 当代医药论丛, 2017, 15(23): 44-47.
[25] Tanaka, F., Yoneda, K., Kondo, N., et al. (2009) Circulating Tumor Cell as a Diagnostic Marker in Primary Lung Cancer. Clinical Cancer Research, 15, 6980-6986. [Google Scholar] [CrossRef] 
[26] 钱芳芳, 罗斌, 阙祖俊, 田建辉. 中医药调控免疫功能防治肺癌的研究进展[J]. 辽宁中医杂志, 2018, 45(5): 1098-1102.
[27] Aldarouish, M., Su, X.Y., Qiao, J.B., et al. (2019) Immunomodulatory Effects of Chemotherapy on Blood Lymphocytes and Survival of Patients with Advanced Non-Small Cell Lung Cancer. International Journal of Immunopathology and Pharmacology, 33. [Google Scholar] [CrossRef] [PubMed]
[28] 胡静, 郑璐, 张欢乐, 张三典, 陆妙珍, 徐国栋, 李旎, 叶爽. CD4+、CD8+T淋巴细胞表达对术后辅助放疗的非小细胞肺癌患者的预后意义[J]. 浙江医学, 2018, 40(7): 712-716+782.
[29] Hu, X.T., Gu, Y., Zhao, S.C., Hua, S. and Jiang, Y. (2019) Elevated Circulating CD4+CD25-Foxp3+ Regulatory T Cells in Patients with Nonsmall Cell Lung Cancer. Cancer Biotherapy & Radiophar-maceuticals, 34, 325-333. [Google Scholar] [CrossRef] [PubMed]
[30] 杜锦芳, 潘树芳, 孙珏, 周诣, 石晓兰. 基于NK细胞的肿瘤免疫研究进展[J]. 现代肿瘤医学, 2016, 24(4): 671-675.
[31] 刘素彤. 非小细胞肺癌患者外周血免疫指标的相关性研究[C]//中国中西医结合学会肿瘤专业委员会. 第十五届全国中西医结合肿瘤学术大会论文集. 中国中西医结合学会肿瘤专业委员会: 中国中西医结合学会, 2017: 1.
[32] 侯东辉, 吴宁. 影像组学在肺癌中的应用进展[J]. 癌症进展, 2019, 17(2): 128-130+144.
[33] Lee, G., Lee, H.Y., Park, H., et al. (2017) Radiomics and Its Emerging Role in Lung Cancer Research, Imaging Biomarkers and Clinical Management: State of the Art. European Journal of Radiol-ogy, 86, 297-307. [Google Scholar] [CrossRef] [PubMed]
[34] 王涛, 王振光. (18)F-FDG PET/CT代谢参数在非小细胞肺癌预后评估中的应用及进展[J]. 中国肺癌杂志, 2019, 22(3): 167-172.
[35] 刘嘉湘. 中医扶正法在肿瘤治疗中的应用[J]. 医学研究通讯, 1973(3): 9-12.
[36] 刘嘉湘. 扶正治癌 融汇中西 继承创新[J]. 中国中西医结合杂志, 2019, 39(1): 10-12.
[37] 刘嘉湘. 中医扶正法治疗支气管肺癌的体会[J]. 新医药学杂志, 1977(10): 17-19.
[38] 陈婧华, 钟文昭. 非小细胞肺癌术后辅助治疗之攻略[J]. 循证医学, 2018, 18(4): 219-221.
[39] 何佩珊, 胡凯文, 冯兴中, 姜敏, 潘国凤, 杨公博, 张可睿. 中医药对老年晚期非小细胞肺癌患者氩氦刀冷冻术后生存期影响的回顾性研究[J]. 中医杂志, 2019, 60(9): 764-767.
[40] 李道睿, 花宝金, 张培彤, 熊露, 刘浩, 林洪生, 朴炳奎. 益肺清化膏对非小细胞肺癌患者术后生存时间延长的临床研究[J]. 中国肿瘤临床与康复, 2017, 24(6): 651-655.
[41] 朱丽华, 李和根, 史美育, 徐蔚杰, 孙建立, 刘苓霜, 赵丽红, 周蕾, 姚逸临. 非小细胞肺癌根治术后无瘤生存期影响因素分析及中药干预效果评价[J]. 上海中医药杂志, 2013, 47(2): 11-15.
[42] 王鹏, 李星晶, 杨文林, 沈芳. 中西医联合治疗非小细胞肺癌术后疗效观察[J]. 辽宁中医药大学学报, 2015, 17(6): 138-140.
[43] 张丽辉, 王兵, 李振宇. 扶正固本散治疗肺癌术后患者31例[J]. 光明中医, 2016, 31(5): 677-679.
[44] 王丽钦, 张娟. 营养支持疗法联合中医艾灸对肺癌根治术后患者生活质量的影响[J]. 中国当代医药, 2017, 24(29): 62-64+74.
[45] 田野, 刘思洋, 姜文军. 芪贞扶正固本汤联合化疗治疗术后非小细胞肺癌40例[J]. 中国中西医结合外科杂志, 2016, 22(3): 242-245.
[46] 董昌盛, 阙祖俊, 朱丽华, 姜怡, 魏静静, 衣秀秀, 钟薏, 李雁, 李和根, 田建辉, 刘嘉湘. 基于循环肿瘤细胞的非小细胞肺癌之“伏毒”本质临证探析[J]. 上海中医药大学学报, 2018, 32(1): 18-22.
[47] 阙祖俊, 罗斌, 钱芳芳, 田建辉. 金复康通过p16/RB信号通路诱导肺癌循环肿瘤细胞衰老[J]. 肿瘤, 2018, 38(3): 215-221.
[48] 毛春晖. 化疗结合中药治疗早期肺癌术后30例对其免疫功能及生存质量的临床观察[J]. 中医药导报, 2007, 13(5): 15-17.
[49] 莫绍雄. 鸦胆子油乳联合化疗对非小细胞肺癌术后患者免疫功能的影响[J]. 现代中西医结合杂志, 2010, 19(9): 1098-1099.
[50] 陈蓉, 李淼, 冀保妍, 亓淑君. 参芪扶正注射液联合化疗治疗非小细胞肺癌术后及对血清中Th17/Treg细胞的调节作用[J]. 中华中医药学刊, 2018, 36(8): 1994-1997.
[51] 寿伟臻, 俞杞泉, 朱正洪, 张宪伟, 钮海弟, 包祺, 吴春晓, 李玉辉. 金宁方加味对Ⅲ期非小细胞肺癌患者术后抗复发转移临床评价[J]. 上海中医药杂志, 2014, 48(8): 30-33.
[52] 张斌杰, 张永奎, 乐涵波, 刘晓光, 徐桂梨, 苏尔云. 非小细胞肺癌术后化疗配合蟾蝓保元汤治疗的作用[J]. 中国中西医结合外科杂志, 2011, 17(5): 458-460.
[53] 郑爱红, 吴国清, 薛骞, 汪霄. 扶正抗癌汤对肺癌术后的临床疗效观察[J]. 中华中医药学刊, 2013, 31(3): 698-700.
[54] 章慧, 王云启, 梁慧. 八珍汤加减治疗非小细胞肺癌术后化疗致骨髓抑制20例总结[J]. 湖南中医杂志, 2011, 27(6): 23-25.
[55] 董颖, 黄建瑾. 地榆升白片预防非小细胞肺癌患者化疗后外周血细胞下降的临床研究[J]. 华西医学, 2009, 24(1): 64-66.

为你推荐